Comparative Pharmacology
Head-to-head clinical analysis: PREVACID versus PREVACID 24 HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREVACID versus PREVACID 24 HR.
PREVACID vs PREVACID 24 HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, thereby suppressing gastric acid secretion.
Proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+-ATPase enzyme system (proton pump) at the secretory surface of gastric parietal cells, suppressing basal and stimulated gastric acid secretion.
15-30 mg orally once daily; or 30 mg orally twice daily for severe GERD.
15 mg orally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours. No significant accumulation with once-daily dosing.
1.2-1.5 hours in healthy subjects; no accumulation with once-daily dosing.
Renal (approx. 70% as metabolites), fecal (approx. 30% as metabolites). Less than 1% excreted unchanged in urine.
Approximately 66% renal (as metabolites), 33% fecal (primarily biliary); less than 1% unchanged in urine.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor